The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
Official Title: A Phase 2 Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL Amyloidosis
Study ID: NCT04617925
Brief Summary: This is an open-label, multicenter, Phase 2 study in subjects with previously treated patients with light chain (AL) amyloidosis in need for therapy. Approximately 35 subjects will receive therapy with belantamab mafodotin. Subject participation will include a Screening Phase, a Treatment Phase, a Post-Treatment Observation Phase, and a Long-term Follow-up Phase. A safety run-in will be conducted in 6 subjects treated with belantamab mafodotin for at least 1 cycle. According to the two-stage statistical design of the study, an interim analysis of efficacy will occur. If after 15 patients have been enrolled at least 3 complete or very good partial responses have been recorded, the accrual will continue until all planned patients have been enrolled
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Centre hospitalier Universitaire de Limoges -, Limoges, , France
University Hospital Heidelberg, Heidelberg, , Germany
General Hospital of Athens "Alexandra", Athens, , Greece
Fondazione I.R.C.C.S Policlinico "San Matteo", Pavia, , Italy
UMC Utrecht, Utrecht, , Netherlands
Royal Free Hospital - London,, London, , United Kingdom